trending Market Intelligence /marketintelligence/en/news-insights/trending/n17qifydqfyn4ec_rtpk9g2 content esgSubNav
In This List

Ablynx's autoimmune disease drug misses main goal in phase 2 study

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Ablynx's autoimmune disease drug misses main goal in phase 2 study

Ablynx NV said its drug vobarilizumab failed to meet the main goal in a phase 2 study for treating the disease known as lupus.

In the trial, dubbed Steady, patients failed to respond to various doses of the drug after 24 weeks. The trial enrolled 312 patients suffering from moderate to severe active seropositive systemic lupus erythematosus.

Lupus is an autoimmune disease in which the immune system mistakenly attacks healthy tissue in different parts of the body, resulting in pain and swelling.

Sanofi is acquiring Ablynx in a €3.9 billion deal, looking to bulk up on therapies for rare diseases.